Lois Hew

Lois Hew

Auto-generated profile, based on publicly available information

Lois Hew

Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
PHPetra Huehnchen
Petra Huehnchen
CSChristian Schinke
Christian Schinke
NBNikola Bangemann
Nikola Bangemann
ADAdam D. Dordevic
Adam D. Dordevic
JKJohannes Kern
Johannes Kern
WBWolfgang Boehmerle
Wolfgang Boehmerle
BACKGROUND: Paclitaxel chemotherapy frequently induces dose-limiting sensory axonal polyneuropathy. Given that sensory symptoms are challenging to assess objectively in clinical practice, an easily accessible biomarker for chemotherapy-induced polyneuropathy (CIPN) holds the potential to improve early diagnosis. Here, we describe neurofilament light chain (NFL), a marker for neuroaxonal damage, as a translational surrogate marker for CIPN. METHODS: NFL concentrations were measured in an in vitro model of CIPN, exposing induced pluripotent stem cell–derived sensory neurons (iPSC-DSNs) to paclitaxel. Patients with breast or ovarian cancer undergoing paclitaxel chemotherapy, breast cancer control patients without chemotherapy, and healthy controls were recruited in a cohort study and examined before chemotherapy (V1) and after 28 weeks (V2, after chemotherapy). CIPN was assessed by the validated Total Neuropathy Score reduced (TNSr), which combines patient-reported symptoms with data from clinical examinations. Serum NFL (NFL s ) concentrations were measured at both visits with single-molecule array technology. RESULTS: NFL was released from iPSC-DSNs upon paclitaxel incubation in a dose- and time-dependent manner and was inversely correlated with iPSC-DSN viability. NFL s strongly increased in paclitaxel-treated patients with CIPN, but not in patients receiving chemotherapy without CIPN or controls, resulting in an 86% sensitivity and 87% specificity. An NFL s increase of +36 pg/mL from baseline was associated with a predicted CIPN probability of more than 0.5. CONCLUSION: NFL s was correlated with CIPN development and severity, which may guide neurotoxic chemotherapy in the future. TRIAL REGISTRATION: ClinicalTrials.gov NCT02753036. FUNDING: Deutsche Forschungsgemeinschaft (EXC 257 NeuroCure), BMBF (Center for Stroke Research Berlin, 01 EO 0801), Animalfree Research, EU Horizon 2020 Innovative Medicines Initiative 2 Joint Undertaking (TransBioLine, 821283), Charité 3R — Replace — Reduce — Refine.

10 February 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
CSChristian Schinke
Christian Schinke
SMSmilla K. Maierhof
Smilla K. Maierhof
LHLois Hew
Lois Hew
VVValeria Fernandez Vallone
Valeria Fernandez Vallone
SFSilke Frahm
Silke Frahm
WBWolfgang Boehmerle
Wolfgang Boehmerle
The microtubule-stabilizing drug paclitaxel remains the standard of care for various solid malignancies but frequently leads to chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a leading cause for premature treatment termination and a significantly reduced quality of life in long-term cancer survivors. The molecular mechanisms of neuro-axonal degeneration, neuroinflammation, and pain in patients treated with paclitaxel remain incompletely understood, and there are currently no predictive biomarkers or preventive treatments. We used human iPSC-derived sensory neurons exposed to paclitaxel to comprehensively model the pathophysiology of CIPN. Neurotoxicity was assessed over time using viability assays and sequential RNA sequencing, as well as deep proteome and lipidomic analyses. We observed a time and dose-dependent decline of cell viability at clinically relevant paclitaxel doses. Sequential RNA sequencing defined JUN as an early immediate gene, followed by the overexpression of genes of the neuronal stress response (e.g., ARID5A, WEE1 , DUSP16, GADD45A ), neuronal injury and apoptotic pathways (e.g., ATF3 , HRK, BBC3 [PUMA] , BCL2L11 [BIM] , CASP3 ), neuroinflammation and nociception ( CALCB , MMP10 , IL31RA , CYSLTR2 , C3AR1, TNFRSF12A ) and neuronal transduction (e.g., CAMK2A , STOML3, PIRT ), while key enzymes of lipid biosynthesis were markedly downregulated (e.g., LSS, HMGCS1 , HMGCR , DHCR24 ). Deep proteome analyses following 48 h of exposure to 100 nM paclitaxel revealed a strong correlation of differentially expressed RNA with proteins, and a marked degradation of essential axonal transport proteins such as kinesins, stathmins, and scaffold proteins. Consistent with the downregulation of rate-limiting enzymes of lipid biosynthesis, lipidome analysis confirmed deregulation of neuronal lipid homeostasis. In summary, paclitaxel induces transcriptomic and proteomic signatures of the neuronal stress response, neuroinflammation, nociception, and disturbed metabolism. These may explain, in part, the clinical phenotype of sensory loss, hypersensitivity, and neuropathic pain frequently observed in patients suffering from CIPN, but constitute pharmacologically addressable targets.

13 November 2025 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
LHLois Hew
Lois Hew
SMSmilla K. Maierhof
Smilla K. Maierhof
AIAndranik Ivanov
Andranik Ivanov
DBDieter Beule
Dieter Beule
VVValeria Fernandez Vallone
Valeria Fernandez Vallone
CSChristian Schinke
Christian Schinke
Chemotherapy-induced peripheral neuropathy (CIPN) affects up to two-thirds of cancer patients undergoing cytotoxic chemotherapy. Here, we used human iPSC-derived sensory neurons (iPSC-DSN) to model CIPN in vitro. Administration of various chemotherapeutic agents (i.e., paclitaxel, vincristine, bortezomib and cisplatin) at clinically applicable concentrations resulted in reduced cell viability, axonal degeneration, electrophysiological dysfunction and increased levels of phosphorylated c-Jun in iPSC-DSN. Transcriptomic analyses revealed that the upregulation of c-Jun strongly correlated with the expression of genes of neuronal injury, apoptosis and inflammatory signatures. To test whether c-Jun plays a central role in the development of CIPN, we applied the small molecule inhibitor of the Jun N-terminal kinase, SP600125, to iPSC-DSN treated with neurotoxic chemotherapy. c-Jun inhibition prevented chemotherapy-induced neurotoxicity by preserving cell viability, axonal integrity and electrophysiological function of iPSC-DSN. These findings identify c-Jun as a key mediator of CIPN pathophysiology across multiple drug types and present preclinical evidence that c-Jun inhibition is an attractive therapeutic target to prevent CIPN.